Corbus Pharmaceutica (CRBP) 3.25 $CRBP
Corbus Pharmaceuticals Receives $5 Million Development Award From Cystic Fibrosis Foundation Therapeutics to Advance Resunab(TM) Clinical Program
Marketwired - Wed Apr 22, 6:05AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (the "Company"
, a clinical stage drug development company focused on the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that it has received a development award for up to $5 million from Cystic Fibrosis Foundation Therapeutics, Inc. ("CFFT", the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. The development award will help support a first-in-patient Phase 2 clinical trial of the Company's oral anti-inflammatory drug Resunab(TM) in adults with cystic fibrosis ("CF".
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Apr 16, 9:00AM CDT
What:
CRBP: 3.25 (+0.48), NDAQ: 48.84 (+0.12)
OTC Markets Group Congratulates Corbus Pharmaceuticals Holdings on Uplisting to NASDAQ from OTCQB Venture Marketplace
PR Newswire - Thu Apr 16, 8:25AM CDT
OTC Markets Group Inc. (OTCQX: OTCM) congratulates Corbus Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, on its uplisting to the NASDAQ Capital Market. Corbus previously traded on OTCQB®, America's venture market for entrepreneurial and development stage companies.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals Announces Initiation of Trading on The Nasdaq Capital Market
Marketwired - Thu Apr 16, 6:35AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company focused on the development and commercialization of treatments for rare, life-threatening inflammatory and fibrotic diseases, announced that its common stock will begin trading today on The Nasdaq Capital Market (NASDAQ) under the current ticker symbol, CRBP.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals Announces Uplisting to The NASDAQ Capital Market
Marketwired - Mon Apr 13, 2:09PM CDT
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab,(TM) for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that the NASDAQ Stock Market LLC has approved the Company's application to have its common stock listed on The NASDAQ Capital Market (NASDAQ). The stock will commence trading on The NASDAQ Capital Market on April 16, 2015, under its existing ticker symbol CRBP.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals Announces Presentation of Positive Data on Anti-Fibrotic Effects of Resunab(TM) in a Preclinical Model of Lung Fibrosis at the Experimental Biology 2015 Scientific Conference
Marketwired - Wed Apr 01, 7:00AM CDT
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), a clinical stage drug development company focused on the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that positive pre-clinical data on the anti-fibrotic effects of Resunab(TM) will be presented today at the Experimental Biology 2015 scientific conference.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals' IND Receives Clearance From FDA to Initiate Phase 2 Trials in Scleroderma With Its Novel Specialized Pro-Resolving Mediator Drug Resunab(TM)
Marketwired - Mon Mar 09, 7:35AM CDT
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), announced today that company's Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) is now open and it is authorized to initiate a Phase 2 clinical study with Resunab(TM) for the treatment of diffuse cutaneous systemic sclerosis (scleroderma).
CRBP: 3.25 (+0.48)
Corbus Plans Multiple Clinical Trials With Resunab In Orphan Indications
Jason Napodano, CFA - at Seeking Alpha - Wed Feb 11, 2:10PM CST
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals to Present at the Leerink Global Healthcare Conference on February 11, 2015
Marketwired - Wed Feb 11, 6:35AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company", an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that it is presenting at the 2015 Leerink Global Healthcare Conference on February 11, 2015, at 3:05 p.m. EST the Waldorf Astoria in New York, New York.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals Reports 2014 Financial Results and Provides 2015 Business Update
Marketwired - Tue Feb 10, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company", an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today its financial results for the year ended December 31, 2014.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
Marketwired - Mon Feb 02, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company", an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that it will be presenting at the 17th Annual BIO CEO & Investor Conference being held February 9-10, 2015, at the Waldorf Astoria in New York, New York.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Marketwired - Wed Jan 07, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company", an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that its Chief Executive Officer, Yuval Cohen, Ph.D., will be presenting at two upcoming investor conferences in January, 2015.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014
Marketwired - Wed Dec 03, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company", an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today it will be presenting at the Oppenheimer & Co. 25th Annual HealthCare Conference being held December 10-11, 2014, at the Crowne Plaza Hotel in New York, New York.
CRBP: 3.25 (+0.48)
Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com
CNW Group - Tue Dec 02, 7:29AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
SMLR: 3.25 (+0.08), CRBP: 3.25 (+0.48), ONVO: 5.14 (+0.67), CYTX: 0.96 (-0.09), IAG: 2.10 (-0.09)
Corbus Pharmaceuticals to Present at VirtualInvestorConferences.com Online Event on December 4, 2014
PR Newswire - Mon Dec 01, 8:42AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company", an emerging growth drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will be presenting at VirtualInvestorConferences.com, a live and interactive online event, on Thursday, December 4, 2014 at 11:30 a.m. Eastern Standard Time.
CRBP: 3.25 (+0.48)
Fort Point Angels Scores First Successful "Exit"
PR Newswire - Mon Dec 01, 8:37AM CST
Fort Point Angels LLC, an angel investment fund that makes seed and early-stage investments in growth-industry companies, announced its first successful "exit" with the initial public offering of Corbus Pharmaceuticals Holdings Inc., of Norwood, MA.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:18AM CST
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals Receives $5 Million Development Award From Cystic Fibrosis Foundation Therapeutics to Advance Resunab(TM) Clinical Program
Marketwired - Wed Apr 22, 6:05AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (the "Company"
, a clinical stage drug development company focused on the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that it has received a development award for up to $5 million from Cystic Fibrosis Foundation Therapeutics, Inc. ("CFFT", the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. The development award will help support a first-in-patient Phase 2 clinical trial of the Company's oral anti-inflammatory drug Resunab(TM) in adults with cystic fibrosis ("CF". CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Apr 16, 9:00AM CDT
What:
CRBP: 3.25 (+0.48), NDAQ: 48.84 (+0.12)
OTC Markets Group Congratulates Corbus Pharmaceuticals Holdings on Uplisting to NASDAQ from OTCQB Venture Marketplace
PR Newswire - Thu Apr 16, 8:25AM CDT
OTC Markets Group Inc. (OTCQX: OTCM) congratulates Corbus Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, on its uplisting to the NASDAQ Capital Market. Corbus previously traded on OTCQB®, America's venture market for entrepreneurial and development stage companies.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals Announces Initiation of Trading on The Nasdaq Capital Market
Marketwired - Thu Apr 16, 6:35AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company focused on the development and commercialization of treatments for rare, life-threatening inflammatory and fibrotic diseases, announced that its common stock will begin trading today on The Nasdaq Capital Market (NASDAQ) under the current ticker symbol, CRBP.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals Announces Uplisting to The NASDAQ Capital Market
Marketwired - Mon Apr 13, 2:09PM CDT
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab,(TM) for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that the NASDAQ Stock Market LLC has approved the Company's application to have its common stock listed on The NASDAQ Capital Market (NASDAQ). The stock will commence trading on The NASDAQ Capital Market on April 16, 2015, under its existing ticker symbol CRBP.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals Announces Presentation of Positive Data on Anti-Fibrotic Effects of Resunab(TM) in a Preclinical Model of Lung Fibrosis at the Experimental Biology 2015 Scientific Conference
Marketwired - Wed Apr 01, 7:00AM CDT
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), a clinical stage drug development company focused on the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that positive pre-clinical data on the anti-fibrotic effects of Resunab(TM) will be presented today at the Experimental Biology 2015 scientific conference.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals' IND Receives Clearance From FDA to Initiate Phase 2 Trials in Scleroderma With Its Novel Specialized Pro-Resolving Mediator Drug Resunab(TM)
Marketwired - Mon Mar 09, 7:35AM CDT
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), announced today that company's Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) is now open and it is authorized to initiate a Phase 2 clinical study with Resunab(TM) for the treatment of diffuse cutaneous systemic sclerosis (scleroderma).
CRBP: 3.25 (+0.48)
Corbus Plans Multiple Clinical Trials With Resunab In Orphan Indications
Jason Napodano, CFA - at Seeking Alpha - Wed Feb 11, 2:10PM CST
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals to Present at the Leerink Global Healthcare Conference on February 11, 2015
Marketwired - Wed Feb 11, 6:35AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that it is presenting at the 2015 Leerink Global Healthcare Conference on February 11, 2015, at 3:05 p.m. EST the Waldorf Astoria in New York, New York. CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals Reports 2014 Financial Results and Provides 2015 Business Update
Marketwired - Tue Feb 10, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today its financial results for the year ended December 31, 2014. CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
Marketwired - Mon Feb 02, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that it will be presenting at the 17th Annual BIO CEO & Investor Conference being held February 9-10, 2015, at the Waldorf Astoria in New York, New York. CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Marketwired - Wed Jan 07, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that its Chief Executive Officer, Yuval Cohen, Ph.D., will be presenting at two upcoming investor conferences in January, 2015. CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014
Marketwired - Wed Dec 03, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today it will be presenting at the Oppenheimer & Co. 25th Annual HealthCare Conference being held December 10-11, 2014, at the Crowne Plaza Hotel in New York, New York. CRBP: 3.25 (+0.48)
Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com
CNW Group - Tue Dec 02, 7:29AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
SMLR: 3.25 (+0.08), CRBP: 3.25 (+0.48), ONVO: 5.14 (+0.67), CYTX: 0.96 (-0.09), IAG: 2.10 (-0.09)
Corbus Pharmaceuticals to Present at VirtualInvestorConferences.com Online Event on December 4, 2014
PR Newswire - Mon Dec 01, 8:42AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"
, an emerging growth drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will be presenting at VirtualInvestorConferences.com, a live and interactive online event, on Thursday, December 4, 2014 at 11:30 a.m. Eastern Standard Time. CRBP: 3.25 (+0.48)
Fort Point Angels Scores First Successful "Exit"
PR Newswire - Mon Dec 01, 8:37AM CST
Fort Point Angels LLC, an angel investment fund that makes seed and early-stage investments in growth-industry companies, announced its first successful "exit" with the initial public offering of Corbus Pharmaceuticals Holdings Inc., of Norwood, MA.
CRBP: 3.25 (+0.48)
Corbus Pharmaceuticals reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:18AM CST
CRBP: 3.25 (+0.48)
